Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 18 von 51

Details

Autor(en) / Beteiligte
Titel
Altered cancer metabolism in mechanisms of immunotherapy resistance
Ist Teil von
  • Pharmacology & therapeutics (Oxford), 2019-03, Vol.195, p.162-171
Ort / Verlag
England: Elsevier Inc
Erscheinungsjahr
2019
Quelle
MEDLINE
Beschreibungen/Notizen
  • Many metabolic alterations, including the Warburg effect, occur in cancer cells that influence the tumor microenvironment, including switching to glycolysis from oxidative phosphorylation, using opportunistic modes of nutrient acquisition, and increasing lipid biosynthesis. The altered metabolic landscape of the tumor microenvironment can suppress the infiltration of immune cells and other functions of antitumor immunity through the production of immune-suppressive metabolites. Metabolic dysregulation in cancer cells further affects the expression of cell surface markers, which interferes with immune surveillance. Immune checkpoint therapies have revolutionized the standard of care for some patients with cancer, but disease in many others is resistant to immunotherapy. Specific metabolic pathways involved in immunotherapy resistance include PI3K-Akt-mTOR, hypoxia-inducible factor (HIF), adenosine, JAK/STAT, and Wnt/Beta-catenin. Depletion of essential amino acids such as glutamine and tryptophan and production of metabolites like kynurenine in the tumor microenvironment also blunt immune cell function. Targeted therapies against metabolic checkpoints could work in synergy with immune checkpoint therapy. This combined strategy could be refined by profiling patients' mutation status before treatment and identifying the optimal sequencing of therapies. This personalized combinatorial approach, which has yet to be explored, may well pave the way for overcoming resistance to immunotherapy.
Sprache
Englisch
Identifikatoren
ISSN: 0163-7258
eISSN: 1879-016X
DOI: 10.1016/j.pharmthera.2018.11.004
Titel-ID: cdi_proquest_miscellaneous_2135135691

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX